ArticlePDF Available

Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder

Authors:

Abstract

Objective: To examine the degree to which South African physicians use similar treatment guidelines in their prescription of antipsychotic medication. Method: Data on the prescriptions for Xhosa patients with schizophrenia and schizoaffective disorder were retrospectively examined to investigate differences between three catchment areas in the Western Cape, especially in terms of clozapine use. Results: There was an overall low rate (10.0%) of clozapine use and a relatively high occurrence of polypharmacy (28.6% of 510 patients). There were statistically significant differences between the three catchment areas in terms of clozapine (p=0.002) and haloperidol (p=0.001) use. Valkenberg hospital had the highest number of clozapine prescriptions and the lowest of haloperidol. Prescriptions of depot antipsychotics did not differ between catchment areas. Conclusion: Discrepancies in antipsychotic medicine prescription patterns were evident between the examined hospitals. It is becoming paramount for practical implementation of guidelines to be improved in South Africa to address, e.g., low clozapine use and the high frequency of polypharmacy.
ORIGINAL Afr J Psychiatry 2008;11:287-290
AAffrriiccaann JJoouurrnnaall ooff PPssyycchhiiaattrryy November 2008 228877
Introduction
Internationally, clinical practice guidelines – such as National
Institute for Clinical Excellence (NICE) guidelines1and
others2,3 – are widely available for the treatment of mental
illness. Although adherence to these guidelines varies4, their
aims are to assist in clinical decision-making and increase the
cost-effectiveness of services by reducing unnecessary
variations in prescribing practices.5In South Africa, mental
illnesses such as schizophrenia impose a heavy financial
burden on health services6, but we do not have uniform
provincial or national guidelines regulating practices in the
treatment of mental illness. We also often have a difference in
ethnic background between clinician and patient, a factor that
could lead to mistaken assumptions that affect the way in
which clinicians adhere to guidelines or make treatment
decisions.7-9 Currently, our standards are inter national
guidelines, which are not specifically adapted to local
circumstances.
The aim of this study is to examine the antipsychotic
prescription patterns for a population with schizophrenia or
schizoaffective disorder, to determine if local practices are
comparable with standard international guidelines. In order to
limit possible confounding factors an ethnically homogenous
group was chosen. We pay particular attention to clozapine
prescription as this was at the time of the study the only
second generation antipsychotic available to the public
service patient population in the Western Cape, where our
study took place. We investigated differences between three
neighbouring areas in the Western Cape, where we expected
treatments to be similar, due to the relatively homogeneous
nature of the population.
Antipsychotic prescription
patterns in Xhosa patients with
schizophrenia or schizoaffective
disorder
L Koen, P Magni, DJH Niehaus, A le Roux
Department of Psychiatry, University of Stellenbosch, Stellenbosch, South Africa
Abstract
Objective: To examine the degree to which South African physicians use similar treatment guidelines in their prescription of
antipsychotic medication. Method: Data on the prescriptions for Xhosa patients with schizophrenia and schizoaffective disorder
were retrospectively examined to investigate differences between three catchment areas in the Western Cape, especially in terms
of clozapine use. Results: There was an overall low rate (10.0%) of clozapine use and a relatively high occurrence of polypharmacy
(28.6% of 510 patients). There were statistically significant differences between the three catchment areas in terms of clozapine
(p=0.002) and haloperidol (p=0.001) use. Valkenberg hospital had the highest number of clozapine prescriptions and the lowest
of haloperidol. Prescriptions of depot antipsychotics did not differ between catchment areas. Conclusion: Discrepancies in
antipsychotic medicine prescription patterns were evident between the examined hospitals. It is becoming paramount for practical
implementation of guidelines to be improved in South Africa to address, e.g., low clozapine use and the high frequency of
polypharmacy.
Keywords: Practice guidelines; Schizophrenia
Received: 03-12-2007
Accepted: 19-02-2008
Correspondence:
Dr L Koen
PO Box 19090, Tygerberg, 7505, South Africa
email: liezlk@sun.ac.za
ORIGINAL Afr J Psychiatry 2008;11:287-290
AAffrriiccaann JJoouurrnnaall ooff PPssyycchhiiaattrryy November 2008 228888
Method
Participants
As part of a large Xhosa genetic study taking place between
2002 and 200510, 510 subjects were recruited from three
“catchment areas” in the greater metropole of Cape Town,
South Africa. These catchment areas consisted of three
hospitals – the Stikland (STH), Lentegeur (LGH) and
Valkenberg (VBH) psychiatric hospitals – and their affiliated
community healthcare clinics (CHCs). These hospitals form
part of one platform of care, namely the Associated Psychiatric
Hospitals (APH). Mental healthcare workers from each of these
centres were asked to identify all possible participants, who
were then screened for suitability based on the following
inclusion criteria: (1) diagnosis of schizophrenia or
schizoaffective disorder according to DSM-IV criteria11 and;
(2) Xhosa ethnicity (four out of four grandparents reported as
of Xhosa origin). Patients were excluded if they had a
significant general medical condition.
Data collection
For the original study10, each subject was inter viewed by a
psychiatrist or an experienced, trained research sister, using
the standardised Diagnostic Interview for Genetic Studies
version 2 (DIGS)12, as well as the Schedule for the Assessment
of Negative Symptoms (SANS)1 3 and the Schedule for the
Assessment of Positive Symptoms (SAPS).14 To ensure inter-
rater consistency over the entire period of recruitment, all
participants were assessed by both raters simultaneously
during the first year of the study. Each participant was
interviewed in their mother tongue, namely Xhosa. The study
was approved by the institutional review board of the
University of Stellenbosch (97/005).
For the purposes of this study, the DIGS and research
folders of all participants were retrospectively examined for
demographic details, type, dose and duration of antipsychotic
drug prescribed, and the catchment area in which the
participant received their treatment. Data were then compared
between the three catchment areas, focusing on differences in
antipsychotic drug prescription, SANS and SAPS scores. The
SANS and SAPS scores of patients using and not using
Clozapine were also compared.
General prescription constraints
At the time of collection of study data conventional
antipsychotics were the only first line treatment available for
prescription to public service patients throughout the Western
Cape. Clozapine was the only atypical freely available but due
to its side-effect profile is considered to be a third-line
treatment (as per international convention), only prescribed
for treatment-resistant patients or patients with prominent side-
effects on conventional antipsychotics.
Results
Demographics
The demographic structures of participants (n=510) were
similar across the three hospitals. Of 510 participants in this
study, 426 (83.5%) were male and 84 (16.5%) female. The
majority (n=403, 79.8%), had never married, 53 (10.5%) were
married, 16 (3.2%), divorced, 18 (3.6%), separated, and 15
(3.0%) were widowed (data on marital status were unavailable
for 5 participants). The mean age at interview was 35.0 years
(range = 15-70, SD = 11.0), whilst the mean age at onset of
illness was 23.3 years (range = 10-55, SD = 6.8). Three
hundred and twenty-two (63.1%) participants were receiving a
disability grant, 165 (32.3%) were unemployed, 18 (3.5%)
were employed, and 1 (0.2%) was a student (data for 4
participants were unknown).
Medication
Fifty-one (10.0%) of the 510 participants were prescribed
clozapine, on a mean dose of 318.0 mg (SD = 188.5 mg), at the
time of interview. The remaining participants were prescribed
as follows: haloperidol 209 (41.0%), chlorpromazine 89
(17.5%), and depot preparation 252 (49.4%). Fluphenazine
was the most common depot preparation prescribed (150 or
59.5% of the 252 prescriptions). Zuclopenthixol was used in 64
patients (25.4%) and Flupenthixol in the remaining 38 patients
(15.1%).
In those using one or more conventional antipsychotics, the
mean dose in chlorpromazine equivalents was 233.2 mg (SD =
220.7 mg). More than one antipsychotic drug was prescribed
to 142 (27.8%) of the patients at the time of interview. The most
frequently used combination was haloperidol and a depot
preparation (n = 77, 54.2%). Of the 51 patients prescribed
clozapine, 11 (22.0%) were also prescribed one or more
conventional antipsychotic.
Clozapine users – clinical profile
The 51 clozapine users had a mean SANS score of 9.8 (SD =
4.8), and a SAPS score of 7.46 (SD 4.4). Those patients not
using clozapine had mean scores of 8.86 (SD 4.1) for SANS
and 6.21 (SD 5.1) for SAPS. Clozapine users had significantly
higher SAPS scores than the non-clozapine users (p = 0.013)
but the SANS scores of the two groups were similar (p = 0.53).
Comparing the three catchment areas
Overall, 87 (17.1%) patients were receiving their treatment in
the STH catchment area. The VBH catchment area consisted of
183 (35.9%) patients, and the LGH catchment area of 240
(47.1%) patients. Thirty-seven (44.6%) of the STH patients
were inpatients, 65 (40.9%) of the VBH and 127 (56.7%) of the
LGH patients were inpatients. VBH therefore had a significantly
lower proportion of inpatients than LGH (p < 0.05).
For clozapine and haloperidol prescriptions, there were
significant differences between the three catchment areas
(Table I). Specifically, VBH had the highest clozapine and
Table I. Main antipsychotic drug prescriptions for Xhosa
patients with schizophrenia or schizoaffective disorder,
compared between the catchment areas for three psychiatric
hospitals in the Western Cape.
Hospital: Lentegeur Stikland Valkenberg
Clozapine*** 14 (5.8%) 8 (10.3%) 29 (15.9%)
Haloperidol*** 108 (50.2%) 45 (57.7%) 58 (34.7%)
Depot 118 (52.9%) 36 (46.2%) 100 (59.9%)
*** p < 0.005
Percentages are the percentage out of each catchment area’s total
number of participants.
Data were missing for 9-17 patients per hospital
ORIGINAL Afr J Psychiatry 2008;11:287-290
AAffrriiccaann JJoouurrnnaall ooff PPssyycchhiiaattrryy November 2008 228899
lowest haloperidol prescriptions. Differences in depot
antipsychotics use were not significant (p>0.05).
The SANS scores of the three areas were similar, but they
differed significantly in terms of SAPS scores (Table II). Patients at
LGH had the highest SAPS score, which differed significantly from
the scores of VBH patients (post-hoc test: p<0.05). The SAPS
scores from STH patients did not differ significantly from either of
the other two catchment areas.
Discussion
This study found an overall rate of 10% clozapine use across
three Western Cape hospitals, which is lower than the clozapine
rates found in Connecticut, USA – 15%15– and Auckland, New
Zeeland – 26%.16One of the possible reasons for the lower-than-
expected rate of clozapine use may be that clinicians in the APH
hospitals feel that patients are less compliant when it comes to
treatment adherence and regular follow-up. This is an important
variable to consider before commencing treatment, as a special
feature of clozapine is a requirement of regular leukocyte counts
to monitor the risk of agranulocytosis.17 However, there is no
supporting evidence that specifically African patients have
poorer treatment adherence rates than patients of other ethnic
groups and this possibility requires further research. The low
frequency of clozapine use may merely reflect practical
implications such as side-effect profile18, repeated white cell
counts and difficulties related to reintroduction of clozapine after
discontinuation for longer than 48 hours .
We found a rate of antipsychotic polypharmacy of 28.6% ,
which compares poorly to studies in New Zealand16 and the
USA15 that found rates of antipsychotic polypharmacy of 13% and
10%, respectively. Antipsychotic polypharmacy is strongly
discouraged in widely-accepted international guidelines,
including the NICE guidelines.1Polypharmacy may lead to an
increased potential for adverse drug effects, unwanted
pharmacokinetic drug interactions, and an increase in the
cumulative antipsychotic dose increasing the risk of tardive
dyskinesia.2,19
There were significant differences between the three
catchment areas in the use of clozapine and haloperidol. One
possible explanation could be that the patients from each hospital
differed in their clinical presentations. The patient profiles may
differ somewhat between catchment areas, as SAPS scores varied
significantly between sites. Interestingly, the lowest SAPS scores
were found in VBH patients, which were also the patients with the
highest clozapine prescription rates. However, clozapine users
overall had significantly higher SAPS scores than non-clozapine
users. Part of the reason for this discrepancy may be that
clozapine treatment has had an effect in VBH already. These
results should be treated with caution, however, as SANS and
SAPS scores serve only as proxy markers of actual clinical
presentations.
The comparison with international prescription rates, and
significant variation within this population suggest a need for
improved regulation of treatment through standardized
guidelines.
Conclusion
In the interests of mental health care in South Africa, it is
becoming necessary for us to implement practical clinical
guidelines, and make these readily available in the large variety
of settings that characterize this country. An important step is for
specialty societies – in our case, the South African Society of
Psychiatrists (SASOP) – to brand local guidelines, such as those
available at STH, to add the necessary credibility.21Local
guidelines need to take into account appropriate resource
allocation22, ethnic and racial variations in pharmacokinetics23,24,
patients' personal preferences9and the careful monitoring of
adverse drug effects.20 Tools that could enhance the use of these
clinical practice guidelines include the provision of a ‘clinical
practice guidelines summary pocket guide’, and clearly visible ,
‘user-friendly’ hospital performance charts and discharge forms
on which the reasoning behind decisions are noted.25 The
combination of monitoring and implementation of evidence-
based practices is reaching new levels of sophistication, with the
introduction of management computer programmes (e.g.20) that
make it easier to implement guidelines in a structured manner.
However, as it can take many years for guidelines to take effect in
general practice26, the time to start addressing this issue, is now.
References
1. National Institute for Clinical Excellence. Schizophrenia - Full national
clinical guideline on core interventions in primary and secondary care.
ISBN 1-901242-97-8. Trowbridge, Wiltshire, UK: Royal College of
Psychiatrists and the British Psychological Society; 2003|.
2. Miller AL, Hal lCS, Buchanan RW, Buckley PF, Chiles JA, Conley RR, et al.
The Texas Medication Algorithm Project antipsychotic algorithm for
schizophrenia: 2003 update. J Clin Psychiatry. 2004;65:500-8.
3. American Psychiatric Association. American Psychiatric Association
Practice Guidelines. Available from:
http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm.
4. Bauer M. A review of quantitative studies of adherence to mental health
clinical practice guidelines. Har v Rev Psychiatry. 2002;10:138-53.
5. Gilbert DA, Altshuler KZ, Rago WV, Shon SP, Crismon ML, Toprac MG, et
al. Texas Medication Algorithm Project: definitions, rationale, and
methods to develop medication algorithms. J Clin Psychiatry.
1998;59:345-51.
6. Seedat S, Emsley RA, Stein DJ. Land of promise: challenges and
opportunities for research in South Africa. Mol Psychiatry. 2004;9:891-2.
7. Kuno E, Rothbard A. Racial disparities in antipsychotic prescription
patterns for patients with schizophrenia. Am J Psychiatry. 2002;159:567-
72.
8. Herbeck DM, West JC, Ruditis I, Duffy FF, Fitek DJ, Bell CC, et al.
Variations in use of second-generation antipsychotic medication by
race among adult psychiatric patients. Psychiatr Serv. 2004;55:677-84.
9. Segal SP, Bola JR, Watson MA. Race, quality of care, and antipsychotic
prescribing practices in psychiatric emergency services. Psychiatr Serv.
1996;47:282-
Table II. The mean (SD) scores of the Schedule for the
Assessment of Negative Symptoms (SANS) and Schedule for
the Assessment of Positive Symptoms (SAPS) for Xhosa
patients with schizophrenia and schizoaffective disorder, in
the catchment areas of three psychiatric hospitals in the
Western Cape.
Hospital: Lentegeur Stikland Valkenberg
SANS score 9.09 (3.82) 8.18 (4.4) 8.94 (4.17)
SAPS score* 6.85 (4.98) 6.71 (5.06) 5.47 (5.02)
* p < 0.05
ORIGINAL Afr J Psychiatry 2008;11:287-290
AAffrriiccaann JJoouurrnnaall ooff PPssyycchhiiaattrryy November 2008 229900
10. Niehaus DJ, Koen L, Laurent C, Muller J, Deleuze JF, Mallet J, et al.
Positive and negative symptoms in affected sib pairs with
schizophrenia: implications for genetic studies in an African Xhosa
sample. Schizophr Res. 2005;79:239-49.
11. American Psychiatric Association. Diagnostic and Statistical Manual of
Mental Disorders: DSM-IV. Fourth Edition ed. Washington, DC:
American Psychiatric Association; 2000.
12. Nurnberger JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG,
Harkavy-Friedman J, et al. Diagnostic interview for genetic studies.
Rationale, unique features and training. NIMH Genetics Initiative. Arch
Gen Psychiatry. 1994;51:849-59.
13. Andreasen NC. The scale for the assessment of negative symptoms
(SANS): conceptual and theoretical foundations. Br J Psychiatry.
1989;7:49-58.
14. Andreasen NC, Arndt S, Miller D, Flaum M, Nopoulos P. Correlation
studies of the scale for the assessment of negative symptoms and the
scale for the assessment of positive symptoms: an overview and update.
Psychopathology. 1995;28:7-17.
15. Covell NH, Jackson CT, Evans AC, Essak SM. Antipsychotic prescribing
practices in Connecticut's public mental health system: rates of
changing medications and prescribing styles. Schizophr Bull.
2002;28:17-29.
16. Wheeler A. Atypical antipsychotic use for adult outpatients in New
Zealand's Auckland and Northland regions. N Z Med J. 2006;119:1237.
17. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA.
Clozapine-induced agranulocytosis -- incidence and risk factors in the
United States. N Engl J Med. 1993 July 15, 1993;329(3):162-7.
18. Lieberman JA, Safferman AZ. Clinical profile of clozapine: Adverse
reactions and agranulocytosis. Psychiatr Q. 1992;63(1):51-70.
19. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia
practice guidelines - international survey and comparison. Br J
Psychiatry. 2005;187:248-55.
20. Joubert AF. Providing quality care to patients with schizophrenia.
Psychiatric Clinics of North America. 2003;26(1):213-30.
21. Leape LL, Weissman JS, Schneider EC, Piana RN, Gatsonis L, Epstein
AM. Adherence to practice guidelines: the role of specialty society
guidelines. Am Heart J. 2003;145:19-26.
22. Rush AJ, Rago VW, Crismon ML, Toprac MG, Shon SP, Suppes T, et al.
Medication treatment for the severely and persistently mentally ill: The
Texas Medication Algorithm Project. J Clin Psychiatry. 1999;60:284-91.
23. Lawson WB. Clinical issues in the pharmacotherapy of African-
Americans. Psychopharmacol Bull. 1996;32:275-81.
24. Lin K, Anderson D, Poland RE. Ethnicity and psychopharmacology:
bridging the gap. Psyciatr Clin North Am. 1995;18:635-47.
25. Brindis R, Sennett C. Physician adherence to clinical practice guidelines:
does it really matter? Am Heart J. 2003;145:13-5.
26. Parks JJ. Implementing practice guidelines: lessons from public mental
health settings. J Clin Psychiatry. 2007;68(suppl 4):45-8.
First Monthly summary of the
Movement for Global
Mental Health
The Movement was launched on October 10th, 2008 and this was announced in an editorial in the
Lancet. You can access this on the website. Since its launch, the Movement has grown impressively.
Until October 30th, these are some key indicators:
293 Institutional Members
31 Institutional Partners
6 Photo Galleries (plus 3 External photo gallery links)
10 Packages of Care
2 Policies
30 Ongoing Research Projects
9 Capacity Building Courses
11 Capacity Building Resources
9 Funders
3 Human Rights Stories
5 Messages of Support
Please keep the momentum going by renewing the message to join through your networks and partners, and getting your own
colleagues and institutions to join up. If we can reach a target of 100 institutions and 1000 individual members by the time of the
summit, we will truly have built up a global coalition for change. Please canvass leaders in your communities to provide 'messages
of support' which can be posted alongside messages from the UN Secretary General, Amartya Sen and other luminaries.
Please also keep on submitting news and events on packages of care, human rights, photo galleries, funders, conferences,
mental health policy documents, research projects and capacity building programs and resources. Oliver Lewis from MDAC has
joined as editor of the human rights pages. If any of you wish to get involved in editing pages, please email the named editors of
those pages (you can find these on the page "About this website" at the bottom of the home page).
Finally, next month we will invite submissions of ideas and suggestions for the program for the Global Mental Health Summit on
September 2nd, 2009 in Athens. The venue has been finalised and the registration fee is 50 euros-book that date now!
(Summary was prepared by Vikram Patel. Suggestions and comments, and volunteers to write these summaries, should be sent to
submissions@globalmentalhealth.org)
... After the first year of treatment, most people will discontinue their use of medications, especially ones where the side effects are difficult to tolerate. [1][2][3][4] Antipsychotic medications have been the main therapeutic approaches for schizophrenia and their diversity can represent the current options of antipsychotic therapies. Since chlorpromazine had been introduced to psychiatric realms in the 1950s, haloperidol, loxapine, perphenazine, molindone and other first-generation antipsychotics followed chlorpromazine in the 1960s. ...
Article
Full-text available
Antipsychotics are a class of agents which are able to reduce psychotic symptoms in a wide range of conditions like schizophrenia, bipolar disorder, psychotic depression, senile psychosis, various organic psychosis and drug induced psychosis. A case study was conducted between February 2014 and august 2014. This study was carried out at the tertiary care hospital, erode. 25 patients were included. On reviewing the prescription the most common disease was found to be schizophrenia followed by acute and chronic psychosis. Age wise it was seen that the diseases were most common in 30-40 years age group. The psychiatric diseases were found to be in males (44%) compared to females (56%).The total no. of drugs prescribed is 135. Of which oral medications 131 (97.03%) and parenteral medications 4 (2.96%). To conclude, our study shows that a were the most common drugs prescribed in patients with and was in accordance with the treatment done in our country and abroad also it was at par with treatment protocol. Olanzapine was the most common medication used followed by risperidone orally. This was a study which was carried out to view treatment schedule in our hospital and its stand with respect to rest of the country.
... 21 Compounding the aforementioned, there is limited research describing the landscape of psychiatric illness and the use of clozapine in our setting. In a study performed in the Western Cape, clozapine use in Xhosa-speaking patients diagnosed with schizophrenia or schizoaffective disorder was low, at 10%, with a rate of antipsychotic polypharmacy almost three times higher, at 28%. 22 Small studies on clozapine users have described the prevalence of clozapine-related side effects, 23 and monitoring patterns of patients on clozapine. 24 However, research describing clozapine prescribing patterns in SA is sparse. ...
Article
Full-text available
Background: Clozapine is the gold standard medication for treatment-resistant psychosis, with robust evidence supporting its efficacy in multiple symptom domains. However, clozapine’s side effect profile contributes to its underutilisation and discontinuation. Aim: This study aimed to explore the magnitude of clozapine use and describe factors that impact on its effective use among in-patients. Setting: Tara Hospital, a specialised psychiatric hospital in Johannesburg. Methods: This was a retrospective, cross-sectional file review of clozapine-treated patients admitted over the 2-year study period. Data variables included: demographics, clinical information, discharge prescription, clozapine-related side effects and details of clozapine discontinuation, where applicable. Results: A cohort of 33.2% of patients from Tara’s biological wards received a trial of clozapine. Participants experienced anti-cholinergic clozapine-related side effects that included weight gain (79.5%), tachycardia (35.2%) and constipation (35.2%). Clozapine was discontinued in 13.7% of participants, and no life-threatening side effects or deaths occurred. Significantly more use of flupenthixol decanoate (64.3% vs. 30.7%; p = 0.0322) and anticholinergics (35.7% vs. 11.4%; p = 0.0474) occurred in the clozapine-discontinued group. Polypharmacy rates were high for psychiatric and non-psychiatric medications. Conclusion: One-third of patients received clozapine trials, most of whom continued at discharge. Although side effects occurred frequently, life-threatening side effects did not. Clozapine monitoring protocols, side effect rating scales, pre-emptive management of side effects, lifestyle interventions and clinician education may improve outcomes of clozapine use. The use of plasma clozapine levels may be beneficial. Contribution: This study expands our limited knowledge regarding current clozapine prescribing trends in South Africa.
... 32 Despite over two decades of research on prescribing practices for LAI -APs globally, 24 there remains a gap in the literature concerning the prescription patterns for LAI -APs in South Africa (SA). Only a few local studies have included information on the prescription of LAI -APs, and these were either limited to patients of only one ethnic group, 33 patients recently discharged from a psychiatric hospital 34 or outpatients attending tertiary psychiatric hospital clinics. 26 Hence, the aim of this study was to examine the prescribing practices for LAI -APs in patients attending community psychiatric clinics in Johannesburg, SA. ...
Article
Full-text available
Background: Long-acting injectable antipsychotics (LAI - APs) improve adherence to antipsychotics and decrease functional decline in schizophrenia. Yet they are prescribed late, in patients with established functional decline. Although LAI - APs are widely prescribed in South Africa, there is a paucity of research regarding the prescription profile for LAI - APs. Aim: This study aimed to describe prescribing practices for LAI - APs at psychiatric clinics. Setting: Community psychiatric clinics in South Africa. Methods: A retrospective review of the psychiatric files of all patients on LAI - APs attending the clinics over the study period was conducted. Sociodemographic, clinical and pharmacological information regarding the LAI - AP prescribed was extracted from the files. Results: A total of 206 charts were examined. The mean age of the study population was 46 (SD ± 12) years. Significantly more patients were male (n = 154; 74.8%), single (n = 184, 89.3%) and unemployed (n = 115; 55.8%) (p < 0.001). Approximately half had a comorbid substance use disorder (47.6%). The most common indication for the prescription of a LAI - AP was non-adherence (66%). Only 9.7% of the patients were prescribed a LAI - AP alone. No significant socio-demographic or clinical characteristic was associated with this prescribing habit. A LAI - AP was prescribed in combination with an oral antipsychotic, mood stabiliser or antidepressant in 53.9%, 44.7% and 7.8% of patients, respectively. Conclusion: Long-acting injectable antipsychotics were prescribed mainly following noncompliance with oral antipsychotics and may represent a missed opportunity to prevent functional decline. The high prevalence of LAI - AP polypharmacy has been highlighted.
... Despite awareness and recommendations to avoid use of combinations unless the testing of antipsychotic therapy in multiple trials, the use of antipsychotic combinations is a common practice [5]. In addition to this all, the patients are often prescribed with two anti-psychotics mostly need doses more than maximum recommendations [2]. Many symptoms and severe side effects are identified due to use of more than one antipsychotic drug at same time. ...
Article
Background: Using antipsychotic polypharmacy is a routine practice despite the instructions and guidelines of avoiding such combinations till several successful trials upon antipsychotic combinations usage. This practice exposes severe side effects over the patient and also poses burden by unnecessary expenses. On the other hand, antipsychotic polypharmacy also has some benefits and most medical practitioners prescribe antipsychotic combinations in order to treat difficult and acute psychosis. Now-a-days, use of antipsychotic polypharmacy is common among psychiatric patients. There is gap due to low empirical evidences in support of its benefits, safety, risks, efficacy and proper way of practicing till now. There is no data available published at local level in Malaysia in spite of recurrent and more prevalent usage of antipsychotic polypharmacy. To determine the proportion and pattern of antipsychotic polypharmacy prescriptions and their possible risks among patients, this study was conducted. Methodology: This cross-sectional study was conducted over the patients prescribed with antipsychotic polypharmacy at Kajang Hospital, Malaysia from June until August 2017. Retrospective data was collected for patients who were admitted in the past 1 year (January 2016 to December 2016). The risk and usage of polypharmacy were assessed on the basis of clinical outcomes and range of prescription as medication non-adherence, adverse drug effects, drug-drug interaction, inappropriate prescriptions, hospitalization, functional decline and mortality resulted either by antipsychotic polypharmacy or due to monotherapy effects. Results: A total of 100 patients were included in this study. Overall there were 120 cases detected in this research. Sixty-two cases out of the total 120 were prescribed antipsychotic monotherapy, while 58 cases prescribed with antipsychotic polypharmacy medications. The use of polypharmacy as antipsychotic medications accounted for almost half of total cases with 48%. It was also found from this study that duration of illness had statistically significant association with antipsychotic polypharmacy (P<0.05). Polypharmacy in antipsychotic treatment caused adverse effects like hyperprolactinemia and EPS. Some other adverse effects were associated with monotherapy and polytherapy medications such as weight gain, hyperlipidemia, and metabolic syndrome but these were not statistically significant. Conclusion: The antipsychotic polypharmacy was high in proportion. Prescription of antipsychotic polypharmacy was concerned with severe side effects. While prescribing antipsychotics for diabetics and obese patients, caution must be taken. To enhance the prevention and management of these medications, there must be more information about risk and usage of antipsychotic polypharmacy.
... Despite awareness and recommendations to avoid use of combinations unless the testing of antipsychotic therapy in multiple trials, the use of antipsychotic combinations is a common practice [5]. In addition to this all, the patients are often prescribed with two anti-psychotics mostly need doses more than maximum recommendations [2]. Many symptoms and severe side effects are identified due to use of more than one antipsychotic drug at same time. ...
Article
Using antipsychotic polypharmacy is a routine practice despite the instructions and guidelines of avoiding such combinations till several successful trials upon antipsychotic combinations usage. This practice exposes severe side effects over the patient and also poses burden by unnecessary expenses. On the other hand, antipsychotic polypharmacy also has some benefits and most medical practitioners prescribe antipsychotic combinations in order to treat difficult and acute psychosis. Now-a-days, use of antipsychotic polypharmacy is common among psychiatric patients. There is gap due to low empirical evidences in support of its benefits, safety, risks, efficacy and proper way of practicing till now. There is no data available published at local level in Malaysia in spite of recurrent and more prevalent usage of antipsychotic polypharmacy. To determine the proportion and pattern of antipsychotic polypharmacy prescriptions and their possible risks among patients, this study was conducted. Methodology: This cross-sectional study was conducted over the patients prescribed with antipsychotic polypharmacy at Kajang Hospital, Malaysia from June until August 2017. Retrospective data was collected for patients who were admitted in the past 1 year (January 2016 to December 2016). The risk and usage of polypharmacy were assessed on the basis of clinical outcomes and range of prescription as medication non-adherence, adverse drug effects, drug-drug interaction, inappropriate prescriptions, hospitalization, functional decline and mortality resulted either by antipsychotic polypharmacy or due to monotherapy effects.
... Polypharmacy was seen in most of the patients (25.5%) and was higher than a study conducted in Nigeria (16). In the present study, the epidemiology of sub- stance abuse polypharmacy was comparable with the studies conducted in Jordan (24.7%), the United States of America (27.5%), and South Africa (28.6%) (17)(18)(19). However, its prevalence was lower as compared to studies conducted in Egypt (37.6%), ...
Article
Full-text available
Background: Substance-use related disorders (SUD) are a major public health concern worldwide, especially in developing nations. Currently, it is characterized by high rates of mortality and morbidity. Moreover, through increased utilization of healthcare services , it causes both direct and indirect significant medical expenditures. Objectives: The current study aimed to evaluate the pattern of Substance abuse in the department of psychiatry of a Tertiary Care Hospital, Srinagar, Jammu, and Kashmir, India. Methods: This is a descriptive, cross-sectional, and open study conducted in the psychiatry inpatient department of a tertiary care hospital, Srinagar, Jammu, and Kashmir, India, for 7 months (January to May 2020). Results: Over a period of seven months, a total of 135 participants were recruited (105 males and 30 females). Most of them were Mus-lim (96.29%), married (68.14%), and living as a nuclear family (75.55%). Tobacco (Nicotine) was the most commonly used substance by those admitted to the psychiatry ward (62.96%), followed by cannabis (11.11%) and opioids (11.11%). The most comorbidity associated with substance abuse was psychiatric disorders (36.84%), followed by neurological disorders (21.05%), and gastrointestinal disorders (7.89%). Among those with psychiatric disorders, 14 (10.37%) had mood (bipolar) disorders. A total of 1129 medicines were prescribed
Article
Full-text available
Aims Women may experience unique mental disorders due to hormone shifts. Rates of schizophrenia and bipolar disorder are similar between genders, but onset and symptoms may differ. Women tend to use more psychotropic drugs due to limited therapeutic options. This study was aimed to estimate the prevalence of psychotropic polypharmacy among females of childbearing potential and factors impacting prescribing patterns. Methods This was a quantitative retrospective chart review for patients admitted to inpatient units at the Mental Health Hospital in Qatar. SPSS® Statistics was used for data analysis. In addition to descriptive statistics applied, linear regression and binary logistic regression models were used to examine the clinical and sociodemographic factors associated with polypharmacy and full therapeutic response upon discharge, respectively. An alpha value of 0.05 was used. Results Of the 347 patients, 52.7% of the patients received a prescription of at least two psychotropic drugs upon discharge. Around two‐thirds (63.1%) were prescribed at least one antipsychotic. Potential predictors of polypharmacy were age (p = 0.027), longer hospital stay (p = 0.003), family history (p < 0.001), absence of suicidal history (p = 0.005), and a diagnosis of a mood disorder (p = 0.009), or a diagnosis of a psychotic disorder (p = 0.015). A full response upon discharge was less likely to occur in patients with a longer stay (OR = 0.940; p = 0.029) and in those with a substance use disorder (OR = 0.166; p = 0.035). Conclusion There is a notably high prevalence of total polypharmacy upon discharge. Some identified factors are modifiable. Evidence‐based prescription practices through hospital guidelines and education should be emphasized to avoid unreasonable polypharmacy.
Preprint
Background The study aimed to investigate the prevalence of APP among Malaysian patients diagnosed with schizophrenia. Methods A descriptive retrospective study was conducted to gather clinical and demographic information on adult individuals diagnosed with psychiatric disorders e.g schizophrenia who had been prescribed with antipsychotic drugs (Antipsychotic combination or Monotherapy) and had been admitted to Hospital Kajang in Malaysia between March 2016 and November 2016. Prevalence of antipsychotic polypharmacy (APP) is determined by determining whether the patient is given one or more antipsychotic medications or not. A descriptive analysis was carried out to evaluate the prevalence of APP among clinical and demographic variables. Results The study included 113 people suffering from schizophrenia. The prevalence of APP was 56.7% (n = 64). According to our results, the prevalence of APP among demographic and clinical variables were 48.4% (n = 31) among elderly patients, 61.8% (n = 40) among males, 70.3% (n = 19) among single, and 67.2% (n = 43) among unemployed schizophrenia patients. Conclusion According to this setting, the proportion of APP in schizophrenia patients is quite high. Being male, single and younger than 50 years of age was linked to a significant rise in APP prevalence; thus, protocols are required to recognize subgroups of psychiatric patients who are most likely benefit from novel management strategies and kidney functions.
Preprint
Full-text available
Background The study aimed to investigate the prevalence of APP among Malaysian patients diagnosed with schizophrenia. Methods A descriptive retrospective study was conducted to gather clinical and demographic information on adult individuals diagnosed with psychiatric disorders e.g schizophrenia who had been prescribed with antipsychotic drugs (Antipsychotic combination or Monotherapy) and had been admitted to Hospital Kajang in Malaysia between March 2016 and November 2016. Prevalence of antipsychotic polypharmacy (APP) is determined by determining whether the patient is given one or more antipsychotic medications or not. A descriptive analysis was carried out to evaluate the prevalence of APP among clinical and demographic variables. Results The study included 113 people suffering from schizophrenia. The prevalence of APP was 56.7% (n = 64). According to our results, the prevalence of APP among demographic and clinical variables were 48.4% (n = 31) among elderly patients, 61.8% (n = 40) among males, 70.3% (n = 19) among single, and 67.2% (n = 43) among unemployed schizophrenia patients. Conclusion According to this setting, the proportion of APP in schizophrenia patients is quite high. Being male, single and younger than 50 years of age was linked to a significant rise in APP prevalence; thus, protocols are required to recognize subgroups of psychiatric patients who are most likely benefit from novel management strategies and kidney functions.
Article
Full-text available
Objectives: In Africa, antipsychotic polypharmacy is growing high due to a high antipsychotic dose prescribing, repeated psychiatric hospitalization, uncontrolled psychotic symptoms, and greater side effect burden. Therefore, the aim of this review and meta-analysis is to assess the prevalence and correlates of antipsychotic polypharmacy among patients with schizophrenia in Africa. Methods: A systematic search was performed from August 1 to 31, 2020 on PubMed, MEDLINE, Google Scholar and Science Direct databases to select articles based on the inclusion criteria. Meta-Analysis of Observational studies in Epidemiology (MOOSE) guidelines were employed. Cross-sectional observational studies which report antipsychotic polypharmacy and/or its correlates in schizophrenia patients in English language published in a peer reviewed journals without time limits were included in the review.The quality of included articles was assessed using Newcastle-Ottawa quality assessment tool. Prevalence and correlates of antipsychotic polypharmacy were the outcome measures of this review and meta-analysis. Open Meta Analyst and RevMan version 5.3 software were used for meta-analysis. A random effect model was used to synthesize data based on the heterogeneity test. Results: Six studies which involve 2,154 schizophrenia patients met the inclusion criteria in this review and meta-analysis. The quality of included studies ranges from 6.5 to 10 based in Newcastle-Ottawa quality assessment tool. The pooled prevalence of antipsychotic polypharmacy among patients with schizophrenia was 40.6% with 95% confidence interval: 27.6% to 53.7%. Depot First Generation Antipsychotics and oral First Generation Antipsychotics were the most commonly prescribed antipsychotic polypharmacy combinations. Socio-demographic, clinical and antipsychotic treatment characterstics were significantly associated with antipsychotic polypharmacy. There was a wide variation in the correlates of antipsychotic polypharmacy assessed by studies and the way that association/correlations was determined and reported. Conclusions: Antipsychotic polypharmacy is common and highly prevalent. Advanced age, male gender, longer duration of schizophrenia, hospital admission and longer antipsychotic treatment were correlates of antipsychotic polypharmacy in Africa.
Article
Full-text available
This study aimed to examine the extent and type of variation in antipsychotic prescription patterns between African American and Caucasian patients with schizophrenia. Subjects were 2,515 adult Medicaid recipients treated for schizophrenia in 1995 with one of four types of antipsychotic medication (traditional antipsychotics, clozapine, risperidone, or depot antipsychotics). Prescription and mental health service use data were collected from Medicaid claims files for the 12 months following the first filled antipsychotic prescription. Patterns of antipsychotic prescription were compared for African American (N=1,538, 61%) and Caucasian (N=977, 39%) subjects. African American subjects were significantly younger and more likely to receive Supplemental Security Income than were the Caucasian subjects, who received mental health services more continuously. African American subjects were less likely than Caucasian subjects to receive clozapine (8% versus 15%, respectively) and risperidone (25% versus 31%) and more likely to receive depot antipsychotics (26% versus 14%). The likelihood of receiving clozapine or risperidone remained significantly different after demographic and service use characteristics were controlled. This study found ethnic disparities in antipsychotic prescription patterns among a large number of publicly insured clients treated for schizophrenia. Given the rapidly changing pharmacological treatment environment, these findings have significant implications for differential quality of care for African American patients. Future studies employing client and provider characteristics are urgently needed to test alternative explanations for ethnic disparities.
Article
Full-text available
We characterized prescribing in Connecticut's State public mental health system to assess the feasibility of implementing an evidence-based medication algorithm. Medication records for a random sample of outpatients with diagnoses of schizophrenia spectrum disorders showed prescribing patterns similar to the entire United States. The base rate of changing antipsychotic medications was moderate. Over half of patients received decanoate medications, polypharmacy was nontrivial, and there was variability in prescribing patterns across physicians. Caucasian patients were more likely to receive an atypical antipsychotic and less likely to have a decanoate medication, and Latino patients were less likely to change medications. Because the base rate of changing medications was moderate and a considerable proportion of patients were prescribed newer antipsychotic medications, introducing a research-derived medication algorithm with newer atypical antipsychotics as first line agents may fit well with current practice. Further, implementing such an algorithm may reduce racial and ethnic disparities in prescribing patterns.
Article
Full-text available
This study examined variations in the use of second-generation antipsychotic medication among African-American and non-Hispanic white patients in a national sample of adults who were treated by psychiatrists. This study used data from studies of psychiatric patients and treatments that were conducted by the American Psychiatric Institute for Research and Education's (APIRE's) Practice Research Network (PRN). Psychiatrists provided detailed clinical data for 126 African-American patients and 574 white patients who were randomly selected and for whom antipsychotic medications were prescribed. The study assessed differences by race in the use of second-generation antipsychotic medication, adjusting for clinical, sociodemographic, and health-system characteristics, including patients' source of payment for treatment. African-American patients were less likely than white patients to receive second-generation antipsychotic medications (49 percent compared with 66 percent). After the analysis statistically adjusted for clinical, sociodemographic, and health-system characteristics, African-American patients remained less likely than white patients to receive second-generation antipsychotics. Because African Americans tended to receive medications that are not first-line recommended treatments and that have a greater risk of producing tardive dyskinesia and extrapyramidal side effects, African Americans could be expected to suffer diminished clinical status. This disparity may also contribute to lower rates of adherence and to more frequent emergency department visits and psychiatric hospitalizations among African Americans
Article
Provides an overview of the issues involved in developing, using and evaluating specific medication guidelines for patients with psychiatric disorders. The potential advantages and disadvantages, as well as the essential elements in the structure of algorithms, are illustrated by experience to date with the Texas Medication Algorithm Project, a public–academic collaboration. Phase 1 entailed assembling research findings on the efficacy of medications for schizophrenic, bipolar, and major depressive disorders. This knowledge was evaluated for its quality and relevance, integrated with expert clinical judgment as well as input by practicing clinicians, family advocates, and patients. Phase 1 (the design and development of the algorithms) was followed by a feasibility test (Phase 2). Phase 3 is an ongoing evaluation comparing the clinical and economic effects of using specific medication guidelines (algorithms) vs treated as usual in public sector patients with severe and persistent mental illnesses. (PsycINFO Database Record (c) 2012 APA, all rights reserved)
Article
Taken together, the literature reviewed clearly indicates that the disposition and effect of a large number of psychotropic agents are influenced substantially by ethnicity and culture. Recent advances in the realm of pharmacokinetics, pharmacogenetics, and pharmacodynamics have led to a greater understanding of some of the mechanisms responsible for such differences. In comparison, much less currently is known regarding how various psychosocial factors impinge on drug responses in different cultural settings. Progress in research in this area is important for clinical reasons, as psychiatric clinicians will increasingly be confronted with patients with divergent ethnic and cultural backgrounds. In addition, knowledge derived from such research will contribute significantly to a better understanding of how the effects of psychotropic agents are mediated, and also should be valuable for the drug development industry that will have to take into account the increasingly diversifying domestic and international markets.
Article
African-Americans have poorer outcomes than Caucasians in general health and mental health systems possibly due to lesser access to services, particularly pharmacotherapy in mental health systems. A review of the literature revealed that African-Americans are more likely to be overdiagnosed as having a psychotic illness. Consequently, antipsychotic medication may be overprescribed. Poorer patient compliance, delays in seeking treatment, higher prescribed dosages, and more PRN use of medication by providers add to racial differences in treatment outcome. African-Americans also are reported to be at a greater risk than Caucasians for medication side effects and adverse consequences. These problems may be exacerbated by ethnic differences in pharmacokinetics. Newer pharmacological agents may be more helpful for minorities because they are better tolerated, produce fewer side effects, and have better efficacy. However, African-Americans still are underrepresented in clinical trials and have limited access to these agents. Race and ethnicity need to be considered in maximizing pharmacotherapy and to better understand treatment outcome.
Article
Background: The Texas Medication Algorithm Project (TMAP), a public-academic collaborative effort, is a 3-phase project to develop, implement, and evaluate medication treatment algorithms for public sector patients with schizophrenia, major depressive disorders, or bipolar disorders. Discussion: This paper, the first in a series describing the activities of the TMAP, focuses on the various definitions and reasons why guidelines have gained popularity. Also discussed are their strengths, the limitations of the various methods used to develop them, and potential barriers to their implementation.
Article
With the increasing use of evidence-based medicine and the welcome introduction of innovations such as computer technology into daily practice, there is now the opportunity to link these two new approaches to the awareness of quality measurement within psychiatry. As awareness of costs in medical treatment increases, the emphasis on quality management increases, which makes it increasingly more important that quality standards are set using the available treatment guidelines. When set, these standards can be applied and eventually measured. Only then can quality management be put into practice. The use of treatment guidelines for the holistic treatment of psychiatry patients now is being actively encouraged in many treatment settings. These guidelines form a potential basis for more effective treatment. Only by implementing a measurement process of treatment outcomes will the true value of these guidelines be appreciated.